牛牛AI助理已提取核心訊息
Shattuck Labs, Inc., a biotechnology company based in Austin, Texas, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on February 29, 2024. The filing pertains to the registration of 1,890,404 shares of common stock for issuance under the Shattuck Labs 2020 Equity Incentive Plan and 472,601 shares for the 2020 Employee Stock Purchase Plan. These plans are designed to offer equity incentives to employees and were previously established in 2020. The company, incorporated in Delaware and led by CEO Dr. Taylor Schreiber, has referenced earlier filings related to these plans dating back to 2020. Shattuck Labs qualifies as a non-accelerated filer, a smaller reporting company, and an emerging growth company under SEC regulations. The filing includes exhibits such as the Amended and Restated Certificate of Incorporation, Bylaws, and opinions from legal counsel, as well as the consent of their independent registered public accounting firm.
Shattuck Labs, Inc., a biotechnology company based in Austin, Texas, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (SEC) on February 29, 2024. The filing pertains to the registration of 1,890,404 shares of common stock for issuance under the Shattuck Labs 2020 Equity Incentive Plan and 472,601 shares for the 2020 Employee Stock Purchase Plan. These plans are designed to offer equity incentives to employees and were previously established in 2020. The company, incorporated in Delaware and led by CEO Dr. Taylor Schreiber, has referenced earlier filings related to these plans dating back to 2020. Shattuck Labs qualifies as a non-accelerated filer, a smaller reporting company, and an emerging growth company under SEC regulations. The filing includes exhibits such as the Amended and Restated Certificate of Incorporation, Bylaws, and opinions from legal counsel, as well as the consent of their independent registered public accounting firm.
總部位於德克薩斯州奧斯汀的生物技術公司Shattuck Labs, Inc. 已於2024年2月29日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件涉及根據沙特克實驗室2020年股權激勵計劃註冊發行的1,890,404股普通股和2020年員工股票購買計劃的472,601股普通股。這些計劃旨在爲員工提供股權激勵，此前已於2020年制定。該公司在特拉華州註冊成立，由首席執行官泰勒·施雷伯博士領導，引用了早些時候與這些計劃相關的文件，這些文件可以追溯到2020年。根據美國證券交易委員會的規定，Shattuck Labs有資格成爲非加速申報人、小型申報公司和新興成長型公司。該文件包括經修訂和重述的公司註冊證書、章程、法律顧問的意見以及其獨立註冊會計師事務所的同意等證據。
總部位於德克薩斯州奧斯汀的生物技術公司Shattuck Labs, Inc. 已於2024年2月29日向美國證券交易委員會（SEC）提交了S-8表格的註冊聲明。該文件涉及根據沙特克實驗室2020年股權激勵計劃註冊發行的1,890,404股普通股和2020年員工股票購買計劃的472,601股普通股。這些計劃旨在爲員工提供股權激勵，此前已於2020年制定。該公司在特拉華州註冊成立，由首席執行官泰勒·施雷伯博士領導，引用了早些時候與這些計劃相關的文件，這些文件可以追溯到2020年。根據美國證券交易委員會的規定，Shattuck Labs有資格成爲非加速申報人、小型申報公司和新興成長型公司。該文件包括經修訂和重述的公司註冊證書、章程、法律顧問的意見以及其獨立註冊會計師事務所的同意等證據。
有用
沒用